Compare SXTP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXTP | GOVX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | 3 | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.0M |
| IPO Year | N/A | N/A |
| Metric | SXTP | GOVX |
|---|---|---|
| Price | $1.49 | $2.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.10 | $1.00 |
| AVG Volume (30 Days) | 54.8K | ★ 9.2M |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $51.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.12 |
| 52 Week High | $8.62 | $4.40 |
| Indicator | SXTP | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 52.14 |
| Support Level | $1.30 | $0.70 |
| Resistance Level | $1.52 | $4.40 |
| Average True Range (ATR) | 0.09 | 0.58 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 54.51 | 28.71 |
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.